Blog
RSS FeedPosted by Michael Wonder on 11 Mar 2018
The relative importance of clinical, economic, patient values and feasibility criteria in cancer drug reimbursement in Canada: a revealed preferences analysis of recommendations of the pan-Canadian Oncology Drug Review 2011–2017
20 January 2018 - Most Canadian provinces and territories rely on the pan-Canadian Oncology Drug Review to provide recommendations regarding public ...
Posted by Michael Wonder on 28 Feb 2018
Digby, N.S., dad obtains high-priced drug to fight rare cancer
25 February 2018 - 'My immediate response is a big sigh of relief. It's a huge stress lifted,' says Jordan Morgan. ...
Posted by Michael Wonder on 16 Feb 2018
Quebec and New Brunswick become first provinces to provide public funding of Ibrance for the first-line treatment of metastatic breast cancer
15 February 2018 - Since Ibrance received Health Canada marketing authorisation in March 2016, Canadian women living with metastatic breast cancer ...
Posted by Michael Wonder on 25 Jan 2018
Pricey drug could help Digby dad fighting rare cancer
25 January 2018 - Jordan Morgan diagnosed with undifferentiated cell sarcoma 4 years ago. ...
Posted by Michael Wonder on 21 Jan 2018
At $262.40 per pill, the cancer drug that could save her life isn’t covered in B.C.
19 January 2018 - Karen McLaren of Langley has stage four breast cancer, and has been prescribed a drug that could ...
Posted by Michael Wonder on 25 Sep 2017
First-in-class BRCA-positive ovarian cancer medicine Lynparza (olaparib) receives positive pan-Canadian Oncology Drug Review recommendation for provincial reimbursement
21 September 2017 - This marks an important first step towards providing Canadian women with access to this treatment. ...
Posted by Michael Wonder on 05 Sep 2017
CADTH recommends olaparib following supply of results from phase 3 trial
5 September 2017 - CADTH has published its initial recommendation for olaparib for use as monotherapy maintenance treatment of adult patients ...
Posted by Michael Wonder on 05 Sep 2017
CADTH publishes final outcome for Opdivo for head and neck cancer
5 September 2017 - CADTH has completed its assessment of nivolumab for the treatment of adults with recurrent or metastatic ...
Posted by Michael Wonder on 03 Aug 2017
CADTH publishes initial recommendation for daratumumab
3 August 2017 - CADTH has published its initial recommendation on the use of daratumumab for use in combination with ...
Posted by Michael Wonder on 03 Aug 2017
CADTH publishes initial recommendation for Keytruda
3 August 2017 - CADTH has published its initial recommendation on the use of pembrolizumab for use by untreated patients ...
Posted by Michael Wonder on 29 Jul 2017
‘It’s very frustrating’: ovarian cancer patient waiting on potential approval of new treatment
27 July 2017 - Seventy-five women are diagnosed with ovarian cancer in Saskatchewan each year, and fifty-five lose their lives. ...
Posted by Michael Wonder on 06 Jul 2017
Canadians living with multiple myeloma need access to therapies now
4 July 2017 - Multiple myeloma, commonly referred to as myeloma, is an incurable cancer of the plasma cells found in ...
Posted by Michael Wonder on 09 Jun 2017
Public funding of approved lung cancer treatments needed now
7 June 2017 - The Canadian Cancer Survivor Network and Lung Cancer Canada are calling on government and industry to ...
Posted by Michael Wonder on 05 Jun 2017
CADTH publishes final outcome for Gazyva for new indication
2 June 2017 - The Canadian pERC has recommended the funding of obinutuzumab (Gazyva) for use by adults with non-Hodgkin's ...
Posted by Michael Wonder on 09 May 2017
Pan-Canadian Oncology Drug Review recommendation supports the use of Tagrisso (osimertinib) as the standard of care for T790M mutated non-small-cell lung cancer
8 May 2017 - AstraZeneca is committed to rapid and collaborative discussions with pan-Canadian Pharmaceutical Alliance and provinces to get ...